113
3
1
9
Cat. No. | Product Name | ||
---|---|---|---|
L9700 | 内质网应激化合物库 | 193 compounds | |
193 个内质网应激相关的化合物集合,可用于高通量和高内涵筛选; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6796 |
CB-5083
CB5083,CB 5083 |
p97 | Ubiquitination |
CB-5083 是一种有效的、选择性的、可口服的 p97 AAA ATPase 抑制剂,IC50为 11 nM。 | |||
T13044 |
Mevociclib
SY-1365 |
CDK | Cell Cycle/Checkpoint |
Mevociclib (SY-1365) 是一种高效选择性 CDK7抑制剂,Ki 值为 17.4 nM。它具有抗血液肿瘤和侵袭性实体肿瘤作用,有抗增殖和凋亡活性。 | |||
T9430 |
Venadaparib
NOV140101,IDX-1197 |
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
Venadaparib (NOV140101) 是一种选择性和具有口服活性的 PARP 抑制剂,对 PARP1和 PARP2的 IC50分别为 1.4 和 1.0 nM。它可防止 DNA 单链断裂 (SSB) 的修复,可研究实体瘤。 | |||
T3124 |
Carbendazim
Bavistin,Carbendazole,多菌灵,Mercarzole |
Antifungal | Microbiology/Virology |
Carbendazim (Mercarzole) 是一种具有抗肿瘤活性的苯并咪唑衍生物,可用于癌症研究。它是一种口服广谱苯并咪唑杀菌剂,可作为真菌疾病研究的杀虫剂。 | |||
T7318 |
Elimusertib
BAY-1895344 |
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Elimusertib (BAY-1895344) 是一种可口服的选择性ATR 抑制剂,IC50值为 7 nM。它具有抗肿瘤活性,可研究实体瘤和淋巴瘤。 | |||
T2325 |
Neratinib
HKI-272,来那替尼 |
EGFR; HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Neratinib (HKI-272) 是一种酪氨酸激酶受体抑制剂,可以抑制 HER2 和 EGFR (IC50=59/92 nM),具有不可逆性和口服活性。Neratinib 具有抗肿瘤活性,可以用于治疗乳腺癌。 | |||
T1601 |
Lomustine
CCNU,NSC 79037,洛莫司汀 |
Apoptosis; Others; DNA Alkylator/Crosslinker; DNA Alkylation; Autophagy | Apoptosis; Autophagy; DNA Damage/DNA Repair; Others |
Lomustine (NSC-79037) 是一种具有抗肿瘤活性的 DNA 烷化剂。 | |||
T26978 |
CEP-40125
RXDX-107 |
DNA Alkylation | DNA Damage/DNA Repair |
CEP-40125 (RXDX-107) 是一种 DNA 烷基剂,可用于研究晚期实体瘤。 | |||
T2619 |
CH5132799
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
CH5132799 是一种选择性的 I 类PI3K 抑制剂。它能够抑制 PI3Kα,其 IC50=14 nM。 | |||
T71924L |
AC 7739
|
Microtubule Associated | Cytoskeletal Signaling |
AC 7739 是一种微管蛋白结合剂,具有抗癌抗肿瘤活性,抑制晚期实体瘤和原位移植肿瘤。 | |||
T36395 |
Trotabresib
CC-90010 |
Epigenetic Reader Domain | Chromatin/Epigenetic |
Trotabresib (CC-90010) 是一种具有口服活性的 BET 抑制剂,可用于晚期实体瘤的研究。 | |||
T76706 |
Varlilumab
CDX-1127 |
TNF | Apoptosis |
Varlilumab (CDX-1127) 是一种新型的人 IgG1 抗 CD27 单克隆抗体。Varlilumab 具有抗肿瘤活性,可用于研究晚期实体肿瘤。 | |||
T15009 |
Elacytarabine
5'-Oleoyl cytosine arabinoside,5'-O-(Elaidoyl) 1-beta-D-arabinofuranosylcytosine,5'-Oleoyl cytarabine,艾西拉滨,CP 4055 |
Others | Others |
Elacytarabine (M7594 0037) 是核苷类似物阿糖胞苷的一种脂质缀合衍生物。Elacytarabine (M7594 0037) (CP 4055) 是一种抗肿瘤药物,在实体瘤中具有细胞毒性。 | |||
T9901A-008 |
Volociximab
Eos 200-4,M200 |
Integrin | Cytoskeletal Signaling |
Volociximab (M200) 是一种靶向 α5β1 整合素的 IgG4 单克隆抗体 ,具有抗血管生成、抗肿瘤和抗癌活性,可抑制兔子 VX2 肿瘤的生长,用于研究实体瘤。 | |||
T12433 |
PF-06952229
PF06952229 |
TGF-beta/Smad | Stem Cells |
PF-06952229 是 TGFβRI 的选择性抑制剂。 PF-06952229 可用于治疗实体瘤,特别是转移性乳腺癌的研究。 | |||
T71137 |
Simmitecan hydrochloride
|
Topoisomerase | DNA Damage/DNA Repair |
Simmitecan hydrochloride 是一种喜树碱衍生物,是一种拓扑异构酶 I 抑制剂,具有抗癌活性,可用于研究是实体瘤。 | |||
T7708 |
DL-Buthionine-(S,R)-sulfoximine
Butionine sulfoximine,丁基硫,NSC 381100,D,L-Buthionine-(S,R)-sulfoximine |
Others; Ferroptosis | Apoptosis; Others |
DL-Buthionine-(S,R)-sulfoximine (Butionine sulfoximine) 是 γ-谷氨酰半胱氨酸合成酶的抑制剂,用于治疗实体瘤。 | |||
T79157 |
Pimicotinib
ABSK021,ABSK-021 |
c-Fms; Others | Others; Tyrosine Kinase/Adaptors |
Pimicotinib (ABSK021) 为一种有效的 CSF1R 抑制剂,具抗肿瘤活性,可用于研究晚期实体瘤。 | |||
T71399 |
Plogosertib
CYC140 |
PLK | Cell Cycle/Checkpoint |
Plogosertib (CYC140) 是一种具有口服活性、选择性、高效性和 ATP 竞争性的 PLK1 抑制剂 ,IC50 值为 3 nM。Plogosertib 具有抗增殖和抗癌活性,可用于研究实体瘤和血液肿瘤。 | |||
T68144 |
Spiroplatin
|
Others | Others |
Spiroplatin(TNO-6)是一种新型含铂类似物,具有抗肿瘤活性,常用用于研究实体肿瘤。 | |||
T2113 |
PHA-793887
PHA 793887,PHA793887 |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
PHA-793887 是一种ATP 竞争性的CDK 抑制剂,可抑制 Cdk2、Cdk1、Cdk4 和 Cdk9 的活性,IC50值分别为 8 nM、60 nM、62 nM 和 138 nM,同时可抑制糖原合酶激酶 3β,IC50值为 79 nM。 | |||
T9929 |
Ramucirumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Ramucirumab 是一种人 VEGFR-2 拮抗剂,具有抗实体瘤活性。它是人源化单克隆抗体,能够与 VEGFR-2 结合,阻碍 VEGFR 配体 VEGF-A,VEGF-C 和 VEGF-D 结合。 | |||
T2503 |
PAC-1
Procaspase activating compound 1 |
Apoptosis; Caspase; Autophagy | Apoptosis; Autophagy; Proteases/Proteasome |
PAC-1 (Procaspase activating compound 1) 是一种 procaspase-3激活剂,诱导癌细胞凋亡,EC50为 2.08 μM,可用于研究淋巴瘤、黑色素瘤、实体瘤、乳腺癌和胸癌等治疗的试验。 | |||
T40199 |
Tulmimetostat
CPI-0209 |
Histone Methyltransferase | Chromatin/Epigenetic |
Tulmimetostat (CPI-0209) 是一种具有口服活性的 EZH1/EZH2 抑制剂。Tulmimetostat 有抗肿瘤活性,用于研究卵巢癌和晚期实体瘤。 | |||
T9901A-002 |
Enoblituzumab
MGA271,TJ-271 |
Others | Others |
Enoblituzumab 是一种人源化 IgG1κ 单克隆抗体,可以识别人 B7-H3 蛋白 ,可用于研究非小细胞肺癌 (NSCLC)等实体肿瘤。 | |||
T13519 |
6-Aminochrysene
6-Chrysenamine |
Others | Others |
6-Aminochrysene (6-Chrysenamine) 是几种实体实验性肿瘤生长的抑制剂,可用于脾肿大、乳腺癌和骨髓性白血病的研究。 | |||
T74698 |
RMC-6236
RMC6236 |
Ras | GPCR/G Protein; MAPK |
RMC-6236 是一种 RAS(ON)MULTI 抑制剂,具有抗癌活性,可用于研究晚期恶性实体瘤和结直肠癌。 | |||
T77138 |
Ragifilimab
INCAGN-01876,INCAGN-1876,CM-701 |
TNF | Apoptosis |
Ragifilimab (INCAGN-1876),一种针对糖皮质激素诱导的TNFR相关蛋白(GITR)的单克隆抗体激动剂,适用于晚期或转移性实体瘤的研究。 | |||
T63260 |
Snail/HDAC-IN-1
|
Apoptosis; Antifungal | Apoptosis; Microbiology/Virology |
Snail/HDAC-IN-1是一种Snail/HDAC 抑制剂剂,具有抗菌抗癌活性, 可降低Snail蛋白的表达,诱导细胞凋亡,可用于研究实体肿瘤。 | |||
T76671 |
Amatuximab
MORab-009 |
Others | Others |
Amatuximab (MORab-009) 是一种人源化针对细胞表面间皮素 (MSLN) 的嵌合 IgG1/k 单抗,具有抗肿瘤活性,可用于治疗实体肿瘤。 | |||
T15168L |
DRF-1042 HCl
DRF-1042 HCl(200619-13-2 Free base) |
Topoisomerase | DNA Damage/DNA Repair |
DRF-1042 HCl 是一种具有口服活性的喜树碱类似物,具有抗肿瘤活性,抑制 DNA 拓扑异构酶 I,可用于研究难治性实体瘤。 | |||
T77750 |
Rosmantuzumab
OMP-131R10 |
Others | Others |
Rosmantuzumab (OMP-131R10) 是一种 人源化抗 R-spondin 3 (RSPO3)单克隆抗体。Rosmantuzumab 具有潜在的抗肿瘤活性,可用于研究晚期复发难治性实体瘤。 | |||
T81263 |
RMC-7977
|
Ras | GPCR/G Protein; MAPK |
RMC-7977 是一种高选择性的 KRAS、HRAS 和 NRAS 活性(GTP 结合)形式的抑制剂,具有抗癌活性,可用于研究KRAS G12C突变的实体瘤。 | |||
T13688 |
Eribulin
ER-086526,E7389,B1939 |
Microtubule Associated; ADC Cytotoxin | Antibody-drug Conjugate/ADC Related; Cytoskeletal Signaling |
Eribulin (B1939) 是非紫杉烷微管动力学抑制剂,具有抗癌活性,通过防止细胞分裂过程中微管的延长和缩短来抑制微管蛋白亚基的聚合。Eribulin 可用于研究转移性乳腺癌和实体瘤。 | |||
T73140 |
MAT2A-IN-9
|
Methionine Adenosyltransferase (MAT) | Chromatin/Epigenetic |
MAT2A-IN-9 是一种 2-oxoquinazoline 衍生物,是一种有效的MAT2A (蛋氨酸腺苷转移酶 2A) 抑制剂。MAT2A-IN-9 具有抗肿瘤活性可用于治疗淋巴瘤和实体瘤。 | |||
T2365 |
Pilaralisib
SAR245408,XL-147 |
PI3K | PI3K/Akt/mTOR signaling |
Pilaralisib (XL-147) 是一种有效的、选择性的 I 类PI3Ks 抑制剂,能够抑制 PI3Kα (IC50:39 nM),PI3Kβ (IC50:383 nM),PI3Kγ (IC50:23 nM) 和 PI3Kδ (IC50:36 nM)。 | |||
T2709 |
TAK-901
TAK901 |
JAK; CDK; Src; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
TAK-901是一种多靶点的极光激酶抑制剂,对极光激酶 A 和 B 的 IC50值分别为 21 和 15 nM。它用于研究淋巴瘤、骨髓纤维化、多发性骨髓瘤、骨髓化生和晚期实体瘤等治疗的试验。 | |||
T72953 |
Zidesamtinib
NVL-520 |
ROS Kinase | Tyrosine Kinase/Adaptors |
Zidesamtinib (NVL-520)是一种具有口服活性、选择性、高效性和可透过血脑屏障的 ROS1 融合和抗性突变抑制剂,抑制 ROS1 和 ROS1 G2032R ,可用于研究非小细胞肺癌和实体瘤。 | |||
T6084 |
Rabusertib
LY2603618,IC-83 |
Chk; PDK; Autophagy | Autophagy; Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling |
Rabusertib (IC-83) 是一种有效的选择性的Chk1抑制剂,IC50为 7 nM。它有潜在的化学增强活性,用于各种癌症和肿瘤治疗的试验。 | |||
T12040 |
Milademetan
RAIN-32,DS-3032,DS3032b |
Mdm2; Others | Apoptosis; Others |
Milademetan (DS-3032) 是一种具有口服活性和有效性的 MDM2 抑制剂,具有抗肿瘤活性,诱导 G1 细胞周期阻滞、衰老和凋亡。Milademetan 可用于研究急性髓系白血病和实体肿瘤。 | |||
T83970 |
IMMH 010 maleate
YPD-30 maleate |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
IMMH 010 maleate (YPD-30 maleate) 是一种可口服的程序性细胞死亡配体 1 抑制剂,具有潜在的抗肿瘤活性,可用于研究神经系统疾病和晚期恶性实体瘤。 | |||
T1890 |
Pracinostat
SB939 |
Apoptosis; HDAC | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair |
Pracinostat (SB939) 是一种组蛋白去乙酰化酶抑制剂,对 HDACs 的IC50值为 40-140 nM,可用于研究癌症。 | |||
T35392 |
Tiragolumab
RO 7092284,RG6058-10,MTIG-7192A,RG6058-11,RG-6058 |
Others | Others |
Tiragolumab(MTIG-7192A) 是一种靶向 T 细胞免疫球蛋白和 ITIM 结构域 (TIGIT) 的单克隆抗体。Tiragolumab (anti-TIGIT) 常与 PD-L1 抑制剂 Atezolizumab 联合使用用来治疗像非小细胞肺癌类的实体恶性肿瘤。 | |||
T3504L |
AZD5153
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
AZD5153 是一种可逆的溴结构域和末端外家族蛋白 BRD4 的抑制剂,具有抗肿瘤活性,通过改变 BRD4 染色体景观和调节 HCC 细胞的转录组来抑制肝癌发生,可用于研究淋巴瘤和实体瘤。 | |||
T0078L |
Lapatinib ditosylate monohydrate
Lapatinib ditosylate monohydrate,Lapatinib ditoluenesulfonate monohydrate,Lapatinib tosilate hydrate,Lapatinib tosilate,Tykerb,二甲苯磺酸拉帕替尼单水合物,Tyverb |
EGFR; Ferroptosis; Autophagy | Angiogenesis; Apoptosis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Lapatinib ditosylate (Lapatinib tosilate) monohydrate 是一种有效的 EGFR 和 ErbB2 抑制剂,对 EGFR 和 ErbB2的 IC50值分别为 10.8 和 9.2 nM。它用于治疗晚期乳腺癌和其他实体瘤。 | |||
T63333 |
Uplarafenib
B-Raf IN 10 |
Raf | MAPK |
Uplarafenib (B-Raf IN 10) 是一种强效的 BRAF 抑制剂,其 IC50 在 50-100 nM 之间。B-Raf IN 10 具有抗肿瘤活性,可能不会影响细胞增殖和分化,可用于研究实体瘤。 | |||
T2156 |
WP1066
|
Apoptosis; JAK; STAT | Angiogenesis; Apoptosis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
WP1066 是一种新型JAK2和STAT3抑制剂,对 STAT5 和 ERK1/2 也起作用。它用于研究黑色素瘤、脑癌、实体瘤和中枢神经系统肿瘤治疗。 | |||
T6157 |
Devimistat
CPI-613,辛酸,CPI613,CPI 613,6,8-Bis(benzylthio)octanoic acid |
Apoptosis; Dehydrogenase; Mitochondrial Metabolism | Apoptosis; Metabolism |
Devimistat (6,8-Bis(benzylthio)octanoic acid) 是一种线粒体代谢抑制剂,还是一种lipoic acid 拮抗剂,能阻断线粒体能量代谢,诱导多种癌细胞凋亡。 | |||
T11500L |
GSK3368715 dihydrochloride
EPZ019997 dihydrochloride,GSK3368715 2HCl,EPZ019997 2HCl |
Histone Methyltransferase | Chromatin/Epigenetic |
GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) 是一种具有口服活性和高效性的 I 型蛋白精氨酸甲基转移酶 (PRMTs) 抑制剂 ,具有抗癌和抗肿瘤活性,抑制PRMT1,PRMT3,PRMT4,PRMT6,PRMT8的活性,可用于研究晚期实体肿瘤。 | |||
T27342L |
Flurocitabine HCl
Flurocitabine HCl(37717-21-8 Free base) |
Others | Others |
Flurocitabine HCl 是阿糖胞苷的氟化酸酐类似物,在体内部分水解成两种活性抗肿瘤物质 (阿拉伯糖基-氟尿嘧啶 (ara-FC) 和阿拉伯糖基-氟尿嘧啶 (ara-FU))。Flurocitabine HCl 在急性白血病和实体瘤的 I 期研究中具显示出抗肿瘤活性。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5724 |
Neogambogic acid
neo-gambogic acid,新藤黄酸 |
Apoptosis; Others; Antibacterial | Apoptosis; Microbiology/Virology; Others |
Neogambogic acid 是藤黄的有效成分,可诱导细胞凋亡并具有抗癌作用。它有效抑制耐甲氧西林的金黄色葡萄球菌。 | |||
T40519 |
Indicine N-oxide
(+)-Indicine N-oxide,Indicine N-oxide,NSC132319 |
Others | Others |
Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, serves as an antitumor agent in pediatric cancer and solid tumors research. | |||
T83110 |
Angulatin K
|
||
Angulatin K为Celastrus angulatus根皮中发现的天然倍半萜多元醇酯。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00008 |
CCL5 Protein, Mouse, Recombinant (hFc)
D17S136E,RANTES,SCYA5,SIS-δ,Ccl5,SISd,eoCP,MuRantes,TCP228,S... |
Mouse | HEK293 Cells |
The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. CCL5 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with N-hFc tag. The predicted molecular weight is 35.2 kDa and the accession number is P30882. | |||
TMPK-00009 |
CCL5 Protein, Human, Recombinant (His & Avi), Biotinylated
RANTES,SIS-δ,D17S136E,TCP228,eoCP,SIS-delta,SCYA5,CCL5,SISd,... |
Human | E. coli |
The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. CCL5 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with N-His-Avi tag. The predicted molecular weight is 10.89 kDa and the accession number is P13501. | |||
TMPK-01081 |
Glypican 2/GPC2 Protein, Mouse, Recombinant (His)
Cerebroglycan,2410016G05Rik,GPC2,Glypican-2 |
Mouse | HEK293 Cells |
Glypicans can function as coreceptors for multiple signaling molecules known for regulating cell growth, motility, and differentiation. Some members of the glypican family, including glypican 2 (GPC2) and glypican 3 (GPC3), are expressed in childhood cancers and liver cancers, respectively. Antibody-based therapies targeting glypicans are being investigated in preclinical and clinical studies, with the goal of treating solid tumors that do not respond to standard therapies. | |||
TMPK-00592 |
Latexin Protein, Human, Recombinant (His)
ECI,TCI,LXN,MUM |
Human | E. coli |
Latexin, the endogenous protein inhibitor of the A/B subfamily of metallocarboxypeptidases, is expressed in small nociceptive neurons in sensory ganglia and in a subset of neurons in the telencephalon. Recently, the latexin (Lxn) gene was identified as a potential tumor suppressor in several types of solid tumors and lymphoma, and Lxn expression was found to be absent or downregulated in leukemic cells. | |||
TMPJ-01207 |
UPP1 Protein, Human, Recombinant (His)
UPP1,Uridine Phosphorylase 1,UPP1 Protein |
Human | E. coli |
Uridinephosphorylase 1 (UPP1) is a member of the family of pentosyltransferase. UPP1 catalyses the reversible phosphorolysis of uridine to uracil. The expression levels and the enzymatic activity of UPP1 are higher in human solid tumors than in adjacent normal tissues. The high level of UPP1 expression in some tumors makes it a potential prognosticfactor for some cancers, such as oral squamous cell carcinoma. UPP1 is important for the homeostatic regulation of intracellular and plasma uridine c... | |||
TMPY-04118 |
Livin/BIRC7 Protein, Human, Recombinant (His)
MLIAP,baculoviral IAP repeat containing 7,RNF50,KIAP,ML-IAP,... |
Human | E. coli |
BIRC7, a new member of inhibitor of the apoptosis protein family, is expressed in fetal tissues and most solid tumors in humans. BIRC7/livin expression is a novel prognostic marker in adult acute leukemia. Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family, which are involved in tumor development through the inhibition of caspases. Livin/BIRC7 is specifically over-expressed in ACC, suggesting that it might be involved in adrenocortical tumorigenesis and represent a new molecu... | |||
TMPY-04936 |
BCL2A1 Protein, Human, Recombinant (His)
BFL1,ACC1,ACC-2,GRS,ACC-1,HBPA1,BCL2 related protein A1,BCL2... |
Human | E. coli |
B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs. Immunohistochemical expression of Wnt11 and BCL2A1 in complete moles and normal villi. Bcl2 family proteins control mitochondrial apoptosis and its members exert critical cell type and differentiation stage-specific functions, acting as barriers against autoimmunity or transformation. Anti-apoptotic Bcl2a1/Bfl1/A1 is frequently der... | |||
TMPY-01583 |
ALDH1A1 Protein, Human, Recombinant (His)
ALDH11,ALDC,PUMB1,ALDH-E1,HEL-S-53e,HEL-9,aldehyde dehydroge... |
Human | E. coli |
Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), also known as Aldehyde dehydrogenase 1 (ALDH1), or Retinaldehyde Dehydrogenase 1 (RALDH1), is an enzyme that is expressed at high levels in stem cells and that has been suggested to regulate stem cell function. The retinaldehyde dehydrogenase (RALDH) subfamily of ALDHs, composed of ALDH1A1, ALDH1A2, ALDH1A3, and ALDH8A1, regulate development by catalyzing retinoic acid biosynthesis. The ALDH1A1 protein belongs to the aldehyde dehydrogenases f... | |||
TMPY-00920 |
SFRP2 Protein, Mouse, Recombinant (His)
secreted frizzled-related protein 2,AI851596,Sdf5 |
Mouse | HEK293 Cells |
The Secreted frizzled-related protein (SFRP) family consists of five secreted glycoproteins in humans (SFRP1~5) that act as extracellular signaling ligands. Each SFRP is approximately 3 amino acids in length and contains a cysteine-rich domain (CRD) that shares 3-5% sequence homology with the CRD of Frizzled (Fz) receptors, a putative signal sequence, and a conserved hydrophilic carboxy-terminal domain. SFRPs are able to bind Wnt proteins and Fz receptors in the extracellular compartment. The in... |